Kisspeptin

What it is

Kisspeptin is a family of endogenous peptides derived from the KISS1 gene. The peptide was originally known as metastin in cancer-biology contexts, but reproductive endocrinology research established kisspeptin signaling as a central regulator of puberty and fertility through activation of the KISS1 receptor^{[7 ]}. In humans, kisspeptin administration can stimulate the hypothalamic-pituitary-gonadal axis, increasing GnRH-mediated release of luteinizing hormone and follicle-stimulating hormone^{[7 –10 ]}.

The most studied clinical forms are kisspeptin-54 and kisspeptin-10. Kisspeptin-54 is a longer peptide used in early human physiology, hypothalamic amenorrhea, and IVF-trigger studies^{[7 –13 ]}. Kisspeptin-10 is a shorter active fragment that has been studied in men and is specifically named in FDA’s compounding-risk materials^{[4 –5 ,10 ]}.

Mechanistically, kisspeptin differs from sex hormones such as testosterone or estrogen. It acts upstream in the reproductive axis by influencing GnRH neurons and therefore LH/FSH release^{[7 –10 ]}. This is why research has investigated kisspeptin in hypothalamic amenorrhea, secondary hypogonadism, assisted reproduction, and psychosexual disorders^{[8 –18 ]}.

Kisspeptin has been administered by intravenous infusion, subcutaneous injection, and intranasal delivery in research studies^{[8 –10 ,19 ]}. These routes are investigational and study-specific. This page does not provide dosing or clinical-use instructions.

Regulatory status

Kisspeptin is not FDA-approved as a prescription drug in the United States. No FDA-approved kisspeptin product label was identified for kisspeptin-10, kisspeptin-54, or related KISS1 receptor agonist uses as of May 7, 2026.

503A bulks-list status — Kisspeptin-10 in Category 2

For 503A compounding, FDA’s framework allows use of bulk drug substances only if they meet the USP/NF monograph pathway, are components of FDA-approved drug products when no monograph exists, or appear on FDA’s 503A bulks list^{[1 ]}. FDA’s April 22, 2026 503A category list places Kisspeptin-10 in Category 2, the category for substances that raise significant safety concerns^{[2 ]}.

FDA’s safety-risk page states that compounded drugs containing Kisspeptin-10 may pose immunogenicity risks for certain routes of administration, may have peptide-impurity and API-characterization complexities, and that FDA has no or only limited safety-related information for the proposed routes of administration^{[4 ]}. FDA therefore states that it lacks sufficient information to know whether the drug would cause harm when administered to humans^{[4 ]}.

October 2024 PCAC vote

The October 29, 2024 PCAC minutes state that FDA reviewed Kisspeptin-10 for secondary hypogonadism in men and that the committee voted 0 yes and 11 no on whether Kisspeptin-10 should be placed on the 503A bulks list^{[5 ]}. The minutes state that the committee unanimously agreed it should not be included because of lack of convincing safety and efficacy data^{[5 ]}.

503B and controlled-substance status

For 503B outsourcing facilities, FDA states that a bulk drug substance must appear on the 503B bulks list or the compounded drug must be on FDA’s shortage list at the time of compounding, distribution, and dispensing^{[3 ]}. No FDA-compliant 503B pathway for routine kisspeptin compounding was identified.

Kisspeptin is not listed in federal controlled-substance schedules in 21 CFR Part 1308 as reviewed on May 7, 2026^{[6 ]}. Date of last regulatory verification: May 7, 2026.

Research summary

Kisspeptin has a stronger human physiology literature than many research peptides. Dhillo and colleagues reported in 2005 that kisspeptin-54 stimulated the hypothalamic-pituitary-gonadal axis in human males^{[7 ]}. George and colleagues later showed that kisspeptin-10 was a potent stimulator of LH and increased LH pulse frequency in men^{[10 ]}. These studies established biological activity in humans but were not approval trials.

Hypothalamic amenorrhea

In hypothalamic amenorrhea, Jayasena and colleagues reported that subcutaneous kisspeptin-54 acutely stimulated gonadotropin secretion, while chronic administration produced tachyphylaxis in one study^{[8 ]}. A later twice-weekly administration study over eight weeks found reproductive hormone stimulation in women with hypothalamic amenorrhea^{[9 ]}. Intravenous kisspeptin-54 infusion also increased LH pulsatility in women with hypothalamic amenorrhea^{[11 ]}. These findings remain investigational and do not create an FDA-approved indication.

IVF oocyte maturation trigger

Assisted-reproduction research has investigated kisspeptin-54 as an oocyte-maturation trigger. Jayasena and colleagues reported that kisspeptin-54 triggered egg maturation in women undergoing IVF^{[12 ]}. Abbara and colleagues later studied women at high risk of ovarian hyperstimulation syndrome and reported kisspeptin-54 efficacy for triggering oocyte maturation^{[13 ]}. A phase 2 randomized trial found that a second dose improved oocyte maturation in women at high OHSS risk^{[14 ]}. These studies support further development but do not mean kisspeptin is an approved IVF trigger in the United States.

Sexual function and HSDD

Kisspeptin has also been studied in sexual and emotional brain processing. Comninos and colleagues reported that kisspeptin modulated sexual and emotional brain processing in humans^{[15 ]}. Subsequent work reported altered resting brain connectivity and enhanced responses to attraction cues^{[16 –17 ]}. Two randomized crossover studies published in JAMA Network Open evaluated women and men with hypoactive sexual desire disorder and reported effects on sexual brain processing and related behavioral measures^{[18 –19 ]}. These are early clinical studies, not approval-enabling evidence.

Newer delivery and receptor agonists

Newer delivery and receptor-agonist research continues. A 2025 EBioMedicine paper reported that intranasal kisspeptin rapidly stimulated gonadotropin release in humans^{[20 ]}. MVT-602, a kisspeptin receptor agonist, has been studied in randomized placebo-controlled trials in healthy premenopausal women with and without ovarian stimulation^{[21 ]}. These developments indicate an active investigational field rather than established clinical availability.

Overall, kisspeptin has credible human mechanistic and early clinical research, especially in reproductive endocrinology. Its regulatory status remains investigational, and FDA has taken a conservative position on Kisspeptin-10 compounding because of limited safety data, immunogenicity and impurity concerns, and insufficient evidence for nominated compounded uses^{[2 ,4 –5 ]}.

Public discourse

Alexander Comninos, MD, PhD, endocrinologist and researcher at Imperial College London, discussed two randomized studies of kisspeptin in women and men with hypoactive sexual desire disorder and framed the results as proof-of-concept rather than established treatment^{[22 ]}.

Waljit Dhillo, MD, PhD, Professor of Endocrinology and Metabolism at Imperial College London, described the HSDD findings as encouraging and called for larger studies and additional populations^{[22 ]}.

In an earlier statement, Dhillo discussed early IVF-trigger research using kisspeptin to stimulate reproductive hormone release^{[23 ]}.

Public discourse reflects the views of the speakers cited and does not represent medical advice or the editorial position of ProPeptideGuide.

Side effects and safety

Clinical studies have generally reported short-term tolerability under controlled research conditions, but the population, route, and dose varied across studies^{[7 –21 ]}. The Imperial HSDD communication reported no side effects in those small studies, but small crossover trials cannot establish long-term safety or rare adverse-event risk^{[18 –19 ,22 ]}.

Mechanism-based concerns

Mechanistic concerns include stimulation of the reproductive endocrine axis, changes in LH/FSH and sex-steroid dynamics, and potential effects in hormone-sensitive conditions. Tachyphylaxis has been observed with chronic subcutaneous kisspeptin-54 administration in hypothalamic amenorrhea, showing that acute hormone responses may not persist in the same way with repeated exposure^{[8 ]}.

FDA compounding concerns

FDA’s compounding concerns focus on immunogenicity, peptide-related impurities, API characterization, and limited safety information for proposed compounded routes^{[4 ]}. These concerns are separate from the controlled settings of academic trials and are especially relevant to compounded or grey-market injectable products.

Long-term safety unknown

No FDA-approved contraindication list, drug-interaction profile, pregnancy/lactation language, or long-term postmarketing safety dataset exists for kisspeptin. Safety in IVF or HSDD trials should not be generalized to unsupervised use, fertility treatment outside trial settings, male secondary hypogonadism treatment, or combination regimens.

Available through

Kisspeptin is not currently available through FDA-compliant prescription or compounding channels in the United States as of 2026-05-07^{[1 –5 ]}. ProPeptideGuide does not link to or endorse grey-market vendors.